BlueCat acquires Men&Mice to boost its industry-leading DNS, DHCP, and IP address management (DDI) platform
Enhanced portfolio will offer organizations of all sizes the tools to simplify and improve their networks
TORONTO, May 17, 2023 (GLOBE NEWSWIRE) -- BlueCat Networks, a leading provider of mission-critical network and cloud infrastructure software for reliable and secure DNS, DHCP, and IP address management (collectively known as DDI), today announced that it has acquired Men&Mice, which provides network management solutions. Regulators approved the deal. Financial terms were not disclosed.
Men&Mice’s industry-recognized IP address management (IPAM) and orchestration solution, Micetro, strengthens BlueCat’s position as a DDI industry leader and further extends BlueCat’s mid-market offerings. BlueCat’s enhanced portfolio addresses the complex requirements of multi-cloud, hybrid cloud, and on-premises environments, which are central to transformation strategies across mid-market and enterprise organizations.
Global demand for DDI management, which provides the core services that direct traffic and enable communication across the network, has increased. A 2022 Future Marketing Insights report projected that the global DDI market would grow by 17% per year, reaching almost $10 billion (USD) by 2032. Digital transformation initiatives are driving this demand as enterprises shift applications to the cloud and deploy infrastructure as code.
As organizations evolve, many use an IPAM solution that also overlays disparate DNS and DHCP solutions to gain visibility, management, and control of their on-premises and cloud environments. Research in 2022 from Enterprise Management Associates revealed that a significant percentage of organizations use an overlay strategy to manage DNS and DHCP from the IPAM environment.
“No matter your size or your stage of network modernization, BlueCat manages DDI across a broad range of environments, with advanced automation, analytics, and security features to simplify network management and performance,” said Stephen Devito, Chief Executive Officer at BlueCat. “We welcome Men&Mice to the BlueCat family and look forward to Micetro’s product evolution. Men&Mice shares BlueCat’s commitment to customer success and a culture of innovation.”
“BlueCat is the right step for the continued growth of Men&Mice and the acquisition recognizes the impact of the employees who helped build and support Micetro and the customers who invested in it,” said Men&Mice Chief Executive Officer Magnus Bjornsson. “We’re committed to supporting our customers and look forward to creating more value in the market.”
About BlueCat
BlueCat is the Adaptive DNS company. The company’s mission is to help organizations deliver reliable and secure network access from any location and any network environment. To do this, BlueCat re-imagined DNS. The result – Adaptive DNS – is a dynamic, open, secure, scalable, and automated DDI management platform that supports the most challenging digital transformation initiatives, like adoption of hybrid cloud and rapid application development. BlueCat’s DDI management platform was recognized as a market leader and outperformer in the 2022 GigaOm Radar report that evaluated all the vendors offering DDI Management. The company is headquartered in Toronto and New York and has additional offices throughout the world, including Germany, the United Kingdom, Japan, Singapore, and Serbia. Learn more at bluecat.com.
About Men&Mice
Men&Mice is one of the oldest tech companies in Iceland and a world leader in sustainable network management. We offer a portfolio of products that makes networks more visible, manageable, resilient, and ultimately safer. Men&Mice was founded in 1990 in Reykjavik, Iceland, to create a management system for schools and fisheries that made administrative tasks simple and transparent. Today, we work with Fortune 500 companies, universities, hospitals, and local governments to make their DNS, DHCP, and IP address management easy. Learn more at menandmice.com.
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
GlobeNewswire by notifiedGlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
ING announces share buyback programme of up to €2.5 billion2.5.2024 07:03:00 CEST | Press release
ING announces share buyback programme of up to €2.5 billion ING announced today a share buyback programme under which it plans to repurchase ordinary shares of ING Groep N.V., for a maximum total amount of €2.5 billion. The purpose of the share buyback programme is to converge our CET1 ratio towards our target of around 12.5%. ING Group’s CET1 ratio was 14.8% at the end of the first quarter of 2024, which is well above the prevailing CET1 ratio requirement of 10.94%. The share buyback programme will have an impact of approximately 77 bps on our CET1 ratio. The programme will commence on 2 May 2024 and is expected to end no later than 29 October 2024. The ECB has approved the programme, which will be executed in compliance with the Market Abuse Regulation and within the limitations of the existing authority to acquire a maximum of 20% of the issued shares as granted by the general meeting of shareholders on 22 April 2024. ING has entered a non-discretionary arrangement with a financial
CEX.IO Launches Mastercard-branded Crypto Debit Card2.5.2024 07:00:00 CEST | Press release
The new product enables registered users in the EEA to make everyday payments with their crypto holdings, and integrates seamlessly with CEX.IO App. VILNIUS, May 02, 2024 (GLOBE NEWSWIRE) -- CEX.IO, a global ecosystem working to bridge the worlds of crypto and traditional finance, announces the debut of CEX.IO Card, a debit card that empowers users to seamlessly spend their crypto assets on everyday purchases. This innovative product marks a pivotal step forward in CEX.IO’s mission to simplify crypto adoption, and bring the benefits of decentralized finance to the masses. The CEX.IO Card seamlessly integrates into users’ existing spending habits, allowing them to effortlessly make purchases with millions of merchants who accept Mastercard, in over 150 countries. Users can fund their cards via a variety of accessible methods, including bank transfers, as well as fiat and crypto deposits. In addition, they may set ranked priorities for their preferred methods, ensuring they always have a
ONWARD® Medical Convocation of the 2024 Annual General Meeting of Shareholders and Proposed Resolutions2.5.2024 07:00:00 CEST | Press release
EINDHOVEN, the Netherlands, May 02, 2024 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD), a medical technology company creating innovative spinal cord stimulation therapies to restore movement, function, and independence in people with spinal cord injury (SCI), today has convened the 2024 Annual General Meeting of Shareholders (AGM), which will include consideration of the resolutions to be submitted for adoption at the AGM, which will be held in Amsterdam, the Netherlands, on June 13, 2024. The resolutions, proposed by the Board, to be submitted for adoption at the AGM, are as follows: Adoption of the Company’s statutory annual accounts for the financial year ended December 31, 2023, prepared in accordance with International Financial Reporting Standards (IFRS-EU). The 2023 statutory accounts were filed with the Netherlands Authority for the Financial Markets (AFM) on April 25, 2024, and are posted on the Company’s website (www.ir.onwd.com) and the AFM's website (afm.nl). Imp
Biotalys Starts Field Trials for Second Biofungicide2.5.2024 07:00:00 CEST | Press release
Ghent, BELGIUM, May 02, 2024 (GLOBE NEWSWIRE) -- Biotalys (Euronext: BTLS) an Agricultural Technology (AgTech) company developing protein-based biocontrols for sustainable crop protection, today announced the initiation of field trials for BioFun-6, the company’s second biofungicide program under development on its AGROBODY technology platform. Kevin Helash, Chief Executive Officer of Biotalys,commented: “Moving BioFun-6 into the field is another important milestone for Biotalys, demonstrating our ability to advance a series of protein-based bioactive ingredients on our platform in concert. As our first product candidate, EVOCA™, progresses through the needed regulatory process and its commercial version EVOCA NG enters its final development stage with our partner Novonesis, we will continue to build our strong pipeline of biofungicides and bioinsecticides to help growers in their transition towards more sustainable practices.” BioFun-6 is a biofungicide targeting botrytis, powdery mil
Press Release: Beyfortus real-world evidence published in The Lancet shows 82% reduction in infant RSV hospitalizations2.5.2024 07:00:00 CEST | Press release
Beyfortus real-world evidence published in The Lancet shows 82% reduction in infant RSV hospitalizations New real-world evidence shows Beyfortus (nirsevimab) substantially reduced RSV lower respiratory tract disease and hospitalizations in infants during the 2023-2024 RSV season, versus no intervention1-6Results add to the consistent high efficacy of Beyfortus against medically attended RSV lower respiratory tract disease, shown in the pivotal clinical studies and the outcomes from HARMONIE, a phase 3b clinical study conducted in close to real-life conditions7-10 Paris, May 2, 2024. Beyfortus reduced respiratory syncytial virus (RSV) hospitalizations by 82% (95% CI: 65.6 to 90.2) in infants under 6 months of age, compared to infants who received no RSV intervention, according to the interim results of an ongoing study published in The Lancet. These results, from the first RSV season after Beyfortus’ introduction, are part of the three-year NIRSE-GAL study conducted in Galicia, Spain un